Tag
This study evaluates the safety and clinical outcomes of immune checkpoint inhibitor rechallenge in classical Hodgkin lymphoma patients following immune-related adverse events, demonstrating feasibility and preserved efficacy in selected ca
In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.
This phase II HD21 trial cohort demonstrates that PET-guided BrECADD chemotherapy is feasible, effective, and well-tolerated in older patients with advanced-stage classic Hodgkin lymphoma, achieving high complete remission and survival rate
The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therap
